ACM
LXEO icon

ADAR1 Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

ADAR1 Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.42M Buy
1,467,350
+74,189
+5% +$526K 0.5% 49
2025
Q4 		$13.8M Sell
1,393,161
-138,792
-9% -$1.27M 1.02% 23
2025
Q3 		$10.2M Buy
1,531,953
+1,386,844
+956% +$6.71M 0.96% 24
2025
Q2 		$583K Sell
145,109
-25,339
-15% -$83.3K 0.09% 109
2025
Q1 		$591K Buy
170,448
+943
+0.6% +$4.18K 0.11% 97
2024
Q4 		$1.12M Buy
169,505
+112,339
+197% +$885K 0.22% 73
2024
Q3 		$517K Buy
57,166
+55,866
+4,297% +$666K 0.08% 111
2024
Q2 		$20.9K Buy
+1,300
New +$18.9K ﹤0.01% 218

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return